(Q37803147)

23 August 2017

title

Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements (English)

1 reference

23 August 2017

Shinji Mizuarai

1

1 reference

23 August 2017

Hidehito Kotani

series ordinal

2

1 reference

23 August 2017

language of work or name

1 reference

26 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

128

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

567-575

1 reference

https://scigraph.springernature.com/pub.10.1007/s00439-010-0900-x

23 August 2017

exact match

0 references

cites work

Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain

1 reference

https://api.crossref.org/works/10.1007%2FS00439-010-0900-X

Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-010-0900-X

Targeting mTOR globally in cancer: thinking beyond rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-010-0900-X

Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-010-0900-X

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

21 January 2018

1 reference

12 December 2020

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

1 reference

12 December 2020

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

12 December 2020

RAS: target for cancer therapy

1 reference

12 December 2020

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

12 December 2020

Use of isogenic human cancer cells for high-throughput screening and drug discovery

1 reference

12 December 2020

Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3

1 reference

12 December 2020

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

12 December 2020

A lethal combination for cancer cells: synthetic lethality screenings for drug discovery

1 reference

12 December 2020

Rapid creation and quantitative monitoring of high coverage shRNA libraries

1 reference

12 December 2020

The wee1 protein kinase is required for radiation-induced mitotic delay

1 reference

12 December 2020

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

12 December 2020

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

1 reference

12 December 2020

Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair

1 reference

12 December 2020

Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells

1 reference

12 December 2020

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

1 reference

12 December 2020

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

1 reference

12 December 2020

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

12 December 2020

mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2.

1 reference

12 December 2020

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

12 December 2020

p21-activated kinases in cancer

1 reference

12 December 2020

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions

1 reference

12 December 2020

Molecular cloning of a new member of the p21-Cdc42/Rac-activated kinase (PAK) family

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

12 December 2020

When mutants gain new powers: news from the mutant p53 field.

1 reference

12 December 2020

RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene

1 reference

12 December 2020

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

1 reference

12 December 2020

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

1 reference

12 December 2020

PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells

1 reference

12 December 2020

P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells

1 reference

12 December 2020

Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets

1 reference

12 December 2020

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

1 reference

12 December 2020

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

1 reference

12 December 2020

Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells

1 reference

12 December 2020

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

1 reference

12 December 2020

Cancer proliferation gene discovery through functional genomics.

1 reference

12 December 2020

Y4 receptor knockout rescues fertility in ob/ob mice.

1 reference

12 December 2020

PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.

1 reference

12 December 2020

Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion

1 reference

12 December 2020

Mechanism of activation of a human oncogene

1 reference

12 December 2020

p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage

1 reference

12 December 2020

The combined status of ATM and p53 link tumor development with therapeutic response

1 reference

12 December 2020

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

1 reference

12 December 2020

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

1 reference

12 December 2020

Lonafarnib in cancer therapy.

1 reference

12 December 2020

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

1 reference

12 December 2020

Second-generation shRNA libraries covering the mouse and human genomes

1 reference

12 December 2020

DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis

1 reference

12 December 2020

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

12 December 2020

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines

1 reference

12 December 2020

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment

1 reference

12 December 2020

10.1007/S00439-010-0900-X

Identifiers

DOI

1 reference

23 August 2017

1 reference